This inventor holds 3 USPTO granted patents and 1 published patent application. Top assignee: Senju Pharmaceutical Co., Ltd.. Active years: 2001-2004.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2001-2004
Title: Keiichi Matsuhisa: Innovator in Aqueous Suspension Technology
Introduction
Keiichi Matsuhisa is a notable inventor based in Himeji, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of aqueous suspensions. With a total of 3 patents to his name, Matsuhisa's work has the potential to enhance various medical applications.
Latest Patents
One of Matsuhisa's latest patents focuses on an aqueous suspension with good redispersibility. This innovative suspension can be prepared by incorporating a water-soluble polymer into an aqueous suspension of a hardly soluble drug. The concentration range is critical, starting from the point where the surface tension begins to decrease and extending to where the reduction in surface tension ceases. The resulting suspension demonstrates excellent redispersibility, preventing the aggregation of dispersed particles or caking. This characteristic makes it particularly useful for parenteral preparations, eye drops, nasal drops, oral administration, and lotions.
Career Highlights
Matsuhisa is currently associated with Senju Pharmaceutical Co., Ltd., where he continues to push the boundaries of pharmaceutical innovation. His work has been instrumental in developing formulations that improve drug delivery and patient outcomes.
Collaborations
Matsuhisa has collaborated with esteemed colleagues such as Shin-ichi Yasueda and Hideo Terayama. Their combined expertise has contributed to the advancement of technologies in the pharmaceutical sector.
Conclusion
Keiichi Matsuhisa stands out as a prominent inventor in the field of aqueous suspension technology. His innovative approaches and collaborations have the potential to significantly impact pharmaceutical formulations and improve patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile